8-K: Tharimmune Secures $1.23 Million in Private Placement of Stock and Warrants

Tharimmune, Inc. has completed a private placement, raising approximately $1.23 million through the issuance of common stock, pre-funded warrants, and common warrants to accredited investors.

Summary

• Tharimmune, Inc. entered into a Securities Purchase Agreement on July 25, 2025, with accredited individual and institutional investors for a private placement.
• The private placement closed on July 31, 2025, generating gross proceeds of $1,225,003.
• The company issued 641,190 shares of common stock.
• Pre-funded warrants to purchase up to 103,490 shares of common stock were issued, with an exercise price of $0.001 per share, exercisable immediately.
• Common warrants to purchase up to 744,680 shares of common stock were issued, with an exercise price of $1.52 per share, exercisable six months from the issuance date (January 25, 2026) and a seven-year term.
• The purchase price for each unit (one share of Common Stock or Pre-Funded Warrant, and one Common Warrant) was $1.645.
• Net proceeds are intended for clinical development and working capital.

Sentiment

Score: 7

Explanation: The filing indicates a successful capital raise, which is positive for the company's financial health and ability to fund operations and clinical development. However, the dilution from new shares and warrants, along with the disclosed related-party transaction, introduce some cautionary elements. The commitment to registration for resale is a strong positive for investors.

Positives

• Successfully raised $1,225,003 in gross proceeds, providing capital for clinical development and working capital.
• The private placement structure includes pre-funded warrants with a nominal exercise price, which can be attractive to investors seeking immediate equity exposure with limited upfront cash outlay.
• The company has committed to filing a registration statement (Form S-3) within 30 days of closing to allow for resale of the securities, which provides a clear path to liquidity for investors.
• The company confirmed that no anti-takeover provisions (like poison pills) apply to the purchasers as a result of this transaction.

Negatives

• The issuance of common stock and warrants will result in dilution for existing shareholders.
• The common warrants have an exercise price of $1.52, which is below the unit purchase price of $1.645, potentially indicating a discount to market or a future dilutive event if exercised.
• A potential conflict of interest exists due to the placement agent's indirect ownership link to the company's largest shareholder.

Risks

• Securities (Shares and Warrant Shares) are restricted and have not been registered, limiting immediate resale unless pursuant to an effective registration statement or Rule 144.
• The company's ability to maintain listing on its Trading Market and secure listing for the newly issued shares and warrant shares is a continuous requirement.
• Failure to timely deliver warrant shares upon exercise could result in liquidated damages payable by the company to the holder ($10 per Trading Day, increasing to $20 after five days).
• The company's financial condition or operational results could experience a Material Adverse Effect, impacting the value of the securities.
• Potential for future dilution from the exercise of warrants.
• The company's Delaware franchise tax delinquency is noted, though not explicitly stated as a material risk in the context of the overall filing.

Future Outlook

The company intends to use the net proceeds from the private placement for clinical development and working capital, indicating a focus on advancing its pipeline and supporting ongoing operations. The commitment to file a registration statement for resale suggests an expectation of future liquidity for investors.

Management Comments

• The company intends to use the net proceeds received from the Private Placement for clinical development and working capital.

Industry Context

This private placement is a common method for biotechnology or pharmaceutical companies like Tharimmune to raise capital for research and development, particularly clinical trials, which are capital-intensive. The structure with warrants is typical for such early-stage or growth companies, offering investors additional upside potential. The use of a placement agent with a disclosed related-party connection is a specific detail that might warrant closer scrutiny in the broader industry context of corporate governance and investor relations.

Comparison to Industry Standards

• The exercise price of $1.52 for common warrants and a nominal $0.001 for pre-funded warrants, combined with a unit price of $1.645, suggests a valuation that may be attractive to investors, especially given the immediate exercisability of pre-funded warrants.
• The beneficial ownership limitation of 4.99% (or 9.99% at holder's election) is a standard provision in such private placements to avoid triggering certain beneficial ownership reporting requirements or takeover provisions.
• The commitment to file a Form S-3 registration statement within 30 days and use commercially reasonable efforts to make it effective within 60 days is a standard and favorable term for investors, providing a clear path to liquidity.
• The liquidated damages clause for failure to timely deliver shares ($10-$20 per trading day per $1,000 of shares) is a common protective measure for investors in private placements to ensure prompt settlement.

Corporate Governance

Related Party Transactions

• Vincent LoPriore, an investment manager at Gravitas Capital LP (the largest shareholder of the Company), is also an indirect owner of the holding company of President Street Global, LLC, which served as the exclusive placement agent for the private placement.
• President Street Global is receiving a monthly retainer and a success fee in connection with this transaction, from which Mr. LoPriore may indirectly benefit.

Stakeholder Impact

• Shareholders: Experience dilution from the issuance of new common stock and the potential exercise of warrants. However, the capital raise strengthens the company's financial position, potentially supporting future growth and value creation.
• Investors (Purchasers): Gain equity exposure and potential upside through common stock and warrants, with a clear path to liquidity via a planned registration statement. They also benefit from protective clauses like liquidated damages for delayed share delivery.
• Employees: A more stable financial position can support ongoing operations and potentially future growth, which benefits employees.
• Creditors: Improved liquidity and financial health from the capital raise could reduce credit risk.

Next Steps

• File a Current Report on Form 8-K with the SEC, including the Transaction Documents as exhibits.
• Issue a press release disclosing the material terms of the transactions.
• File a registration statement on Form S-3 (or other appropriate form) within 30 days following the Closing Date for the resale of the Securities.
• Use commercially reasonable efforts to cause the registration statement to become effective within 60 days following its filing.
• Apply to list all newly issued Shares and Warrant Shares on Nasdaq.
• Use net proceeds for clinical development and working capital.

Key Dates

Recommendation

The capital raise provides necessary funding for clinical development and working capital, which is a positive for the company's operational stability and future prospects. However, the significant dilution from the issuance of new shares and warrants, coupled with the disclosed related-party transaction involving the placement agent and a major shareholder, introduces elements of caution. While the commitment to register shares for resale offers a clear exit path for investors, the immediate impact of dilution and the potential for further dilution upon warrant exercise suggest a 'hold' recommendation. Investors should monitor the company's progress in clinical development and how the new capital is deployed, as well as the market's absorption of the new shares.

Keywords

Tharimmune, Private Placement, Common Stock, Pre-Funded Warrants, Common Warrants, Capital Raise, SEC Filing, 8-K, Securities Purchase Agreement, Clinical Development, Working Capital, Dilution, Nasdaq